BridgeBio Pharma, Inc. (BBIO) Balance Sheet

Total assets grew modestly from $849M to $1.2B over the period, but liabilities ballooned from $1.9B to $3.7B, driven by rising debt and operating obligations. The persistent negative equity indicates that the company is financing its operations through debt and dilution, which may signal a weakening balance sheet trajectory. Investors should monitor whether Attruby's revenue growth can eventually reverse this trend, but current data suggests continued erosion.

The dramatic spike in debt in 2026Q1, followed by a collapse to just $18.3M in 2026Q2, suggests a conversion or repayment of a large debt facility, possibly through equity issuance or asset sales. This volatility implies that BridgeBio's leverage is not stable and may be driven by necessity rather than strategic choice. The absence of a D/E ratio in the data limits direct comparison, but the negative equity base means any debt adds significant financial risk, especially if cash flows remain negative.

The minimal fixed assets and goodwill suggest that BridgeBio's value lies in its pipeline and intellectual property, not physical infrastructure. This structure reduces capital intensity but also means that asset impairments, particularly on goodwill, could have outsized impacts. The slight decline in goodwill from $28.8M to $26.6M may indicate prior impairments, and investors should watch for further write-downs if pipeline assets lose value.

The deepening negative retained earnings reflect cumulative losses that have not been offset by profits, a common pattern for pre-commercial biotechs. However, the magnitude of negative equity (-$2.5B) is substantial and may limit financial flexibility. The recent share repurchases, as noted in the cash flow analysis, appear counterintuitive given the equity deficit, suggesting management is prioritizing share price support over balance sheet repair. This could exacerbate dilution if additional capital is needed.

The current ratio's sharp drop from 5.54 in 2024Q1 to 1.15 in 2026Q2 suggests that current liabilities have grown faster than current assets, possibly due to increased commercial payables and debt maturities. Despite strong revenue growth from Attruby, cash levels have not increased proportionally, implying that operating cash flows remain negative. With a current ratio near 1.0, BridgeBio may face liquidity constraints if it cannot secure additional funding or achieve cash flow positivity soon.